References
- Trigg M.E., Gaynon P., Uckun F.M. Acute lymphoblastic leukemia in children. Cancer Medicine, 4th edition, J.F. Holland, E.I. Fry, R.C.J. Bast, D.W. Kufe, D.L. Morton, R.R. Weichselbaum. Williams & Wilkins, Philadelphia, PA 1996; 1–15
- Pui C.H. Childhood leukemias. New Engl J Med 1995; 332: 1618–1630
- Rivera G.K., Pinkel D., Simone J.V., Hancock M.L., Crist W.M. Treatment of acute lymphoblastic leukemia. N Engl J Med 1993; 1289–1295
- Poplack D.J. Acute lymphoblastic leukemia. Principles and Practice of Pediatric Oncology, P.A. Pizzo, D.G. Poplack. J. B. Lippincott, Philadelphia, PA 1989; 323–366
- Sallan S.E., Weinstein H.J. Childhood acute leukemia. Hematology of Infancy and Childhood, 3rd edition, D.G. Nathan, A. Foski. W. B. Saunders Co., Philadelphia, PA 1987; 1028–1063
- Ortega J.A., Nesbit M.E., Jr., Donaldson M.H., Hittle R.E., Weiner J., Karon M., Hammond D. L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. Cancer Res 1977; 37: 535–540
- Feig S.A., Ames M.M., Sather H.N., Steinherz L., Reid J.M., Trigg M., Pendergrass T.W., Warkentin P., Gerver M., Leonard M., Bleyer W.R., Harris R.E. Comparison of idarubicin to daunorubicin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: A report from The Children's Cancer Group. Med Pedialr Oncol 1996; 27: 505–514
- Simone J.V. Optimal current treatment of childhood acute lymphoblastic leukemia. Cancer Treat Rep 1981; 65(Suppl. 4)97–100
- Uckun F.M. Immunotoxin therapy of human lymphoid malignancies. Br J Haematol 1993; 85: 435–438
- Uckun F.M., Reaman G.H. Immunotoxins for treatment of leukemia and lymphoma. Leuk Lymphoma 1995; 18: 195–201
- Irvin J.D., Uckun F.M. Pokeweed antiviral protein: ribosome inactivation and therapeutic applications. Pharmacol Ther 1992; 55: 279–302
- Uckun F.M., Chelstrom L.M., Finnegan D., Tuel-Ahlgren L., Manivel C., Irvin J.D., Myers D.E., Gunther R. Effective immunochemotherapy of CALLA+Cu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide. Blood 1992; 79: 3116–3129
- Uckun F.M., Manivel C., Arthur D., Chelstrom L.M., Finnegan D., Tuel-Ahlgren L., Irvin J.D., Myers D.E., Gunther R. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency. Blood 1992; 19: 2201–2214
- Uckun F.M., Gajl-Peczalska K.J., Kersey J.H., Houston L.L., Vallera D.A. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing poke-weed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. J Exp Med 1986; 163: 347–368
- Waddick K.G., Myers D.E., Gunther R., Chelstrom L.M., Chandan-Langlie M., Irvin J.D., Turner N., Uckun F.M. In vitro and in vivo antileukemic activity of B43-pokeweed antiviral protein against radiation-resistant human B-cell precursor leukemia cells. Blood 1995; 86: 4228–4233
- Myers D.E., Irvin J.D., Smith R.S., Kuebelbeck V.M., Uckun F.M. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD 19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials. J Immunol Methods 1991; 136: 221–37
- Uckun F.M. Severe combined immunodeficient mouse models of human leukemia. Review article. Blood 1996; 88: 1135–1146
- Messinger Y., Yanishevski Y., Avramis V., Ek O., Chelstrom L., Gunther R., Myers D., Irvin J., Evans W., Uckun F.M. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabi-noside. Clinical Cancer Research 1996; 2: 1533–1542